TransMedics Group, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparative period is Q1 2022. TransMedics is a commercial-stage medical technology company selling its Organ Care System (OCS) for heart, lung and liver transplantation. Its U.S. National OCS Program (NOP) provides organ retrieval and OCS management services. The company reports as one operating segment.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Total revenue | $41.6 million | $15.9 million; up $25.7 million, or approximately 162% |
| Product revenue | $34.0 million | $14.9 million |
| Service revenue | $7.6 million | $0.9 million |
| Gross profit / gross margin | $28.8 million / approximately 69% | $12.1 million / approximately 76% |
| Operating expenses | $30.9 million | $21.5 million |
| Net loss | $2.6 million; $(0.08) per diluted share | $10.6 million; $(0.38) per diluted share |
| Cash used in operating activities | $8.7 million | $18.4 million |
| Cash and cash equivalents at period end | $195.4 million | $201.2 million at December 31, 2022 |
| Debt | $60.0 million principal; $58.8 million net carrying amount | $60.0 million principal at December 31, 2022 |
Product gross margin improved to 79% from 77%, while service gross margin declined to 27% from 58%, reflecting the NOP’s expansion and the comparison with its initial launch period. The lower overall gross margin primarily reflects the larger contribution from services. Operating expenses included $5.9 million for research, development and clinical trials and $25.0 million for selling, general and administrative expenses.
Operating cash use reflected a $11.0 million increase in accounts receivable and a $3.6 million increase in inventory, partly offset by higher payables and accrued liabilities. Investing activities used $0.9 million, primarily for property and equipment; financing activities provided $4.0 million, mainly from option exercises and employee stock purchases. Current assets were $261.7 million and current liabilities $28.6 million at March 31.
Material changes and business drivers
- U.S. revenue rose to $37.5 million from $13.6 million, mainly on higher OCS Liver and Heart sales and NOP expansion. U.S. Lung revenue declined. NOP-participant revenue represented approximately 94% of U.S. revenue, versus 78% a year earlier.
- Revenue outside the United States increased to $4.1 million from $2.3 million, principally due to higher OCS Heart disposable-set sales.
- SG&A increased $11.0 million, driven by personnel and stock-based compensation, NOP logistics, and professional and consulting costs. R&D and clinical-trial expense decreased $1.7 million, largely due to timing of next-generation development work and completion of certain premarket trial enrollment.
- Accounts receivable increased from $27.6 million at year-end to $38.6 million; inventory increased from $20.6 million to $24.0 million.
Outlook, risks and contingencies
- The filing provides no quantified 2023 revenue or earnings guidance. Management expects continued losses in the foreseeable future while investing in commercial growth, NOP expansion, manufacturing and sterilization capacity, product development, and regulatory efforts.
- Management believes $195.4 million of cash at March 31 will fund operations, capital expenditures and debt service for at least 12 months after filing. This estimate depends on assumptions; the company says additional financing may be needed and may not be available on acceptable terms.
- The $60 million CIBC loan bears variable interest; its stated rate was 6.6% at March 31, 2023. Maturity is July 2027. Revenue milestones achieved in the quarter permit a one-year extension of the interest-only period. The debt is secured by substantially all company and guarantor assets, including intellectual property, subject to exceptions. The company reported covenant compliance at quarter-end.
- In March 2023, HRSA announced plans to seek proposals to manage the Organ Procurement and Transplantation Network, whose existing contract was due to expire in September 2023. The filing says the effect on the business, including NOP, was uncertain.
- The filing identifies risks including scaling manufacturing and sterilization, reliance on some limited-source suppliers and sterilization services, reimbursement and market adoption, competition, regulatory requirements, transport dependence, and possible supply-chain, labor, inflation and pandemic disruptions.
- After quarter-end, during Q2 2023, the company became aware of an infiltration of portions of its IT network and identified unauthorized theft of employee and financial data. The investigation was ongoing; the company said it did not store patient-related data on its network or premises. Additional safeguards had been implemented, but their effectiveness and insurance coverage were not assured.
- No material legal proceedings were reported. The company disclosed a non-cancellable purchase commitment with $7.0 million remaining at March 31, 2023, extending through 2029.
Important facts for investors to verify
- Whether rapid revenue growth, especially from the U.S. NOP and Heart and Liver products, continues and converts into cash.
- Whether NOP service margins recover as operations scale, given the decline to 27% from 58%.
- Collection timing for rising receivables and the working-capital requirements of continued growth.
- Progress and disclosures concerning the Q2 cybersecurity incident, including investigation findings, remediation costs and any legal or regulatory consequences.
- Capacity to meet demand, maintain supplier and sterilization availability, and comply with CIBC revenue and liquidity covenants.
- How changes to OPTN management, reimbursement, and international regulatory approvals affect NOP and OCS adoption.